Company / FCF Margin
ALNYLAM PHARMACEUTICALS, INC. FCF Margin History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
12.5%
FY2025
5-year range
-190.5% / 12.5%
FY2021-FY2025
Trend
+763.0%
vs FY2024
Sector context
#42 of 133
Health Care
What the data says
FCF Margin changed +763% YoY in FY2025, a notable deviation from the 7-year average annual change of +107%.
Based on SEC 10-K filings.
12.5% in FY2025 with a 5-year CAGR of +933.0%.
Improved from 2.3% to 12.5% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +151.6pp
- 5-Year Change
- +933.0pp
- 10-Year Change
- -
Sector benchmark
#42 of 133 in Health CareTop 32% of 133This company 12.5% Sector average -632.8%
▼
+102.0% above sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 763.0% year-over-year.
- Currently 645.4pp above the Health Care sector average.
- Lowest fcf margin in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 12.5% | +763.0% |
| FY2024 | -1.9% | -182.5% |
| FY2023 | 2.3% | +101.6% |
| FY2022 | -139.1% | +27.0% |
| FY2021 | -190.5% | +79.3% |
| FY2020 | -920.5% | -69.9% |
| FY2019 | -541.6% | +31.4% |
| FY2018 | -789.4% | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026